About AST

Timeless Core Ideology

Core Ideology describes an organization’s consistent identity that transcends all changes related to its relevant environment. Core ideology consists of two elements: Core Purpose – the organization’s reason for being –and Core Values – essential and enduring principles that guide the behavior of an organization.

Mission Statement:
The American Society of Transplantation is an organization of professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation.

Core Purpose:
Improving human life by advancing the field of transplantation

Core Values:
The principles that guide the AST’s internal conduct and its relationship with the external world.

  • Patient-centered
  • Inclusive and responsive
  • Transformative
  • Global perspective
  • Absolute integrity
  • Knowledge sharing

Long Term Envisioned Future (10+ years)

The envisioned future conveys a concrete yet unrealized future for the organization. It consists of a long term vision – a clear and compelling catalyst that serves as a focal point for effort and a vivid description of a desired future which is a vibrant and engaging description of what it will be like to achieve the long term vision.

Long Term Vision: Double transplant survival and optimize the quality of patients’ lives while improving access to transplantation for all in need.

Vivid Description of a Desired Future: The American Society of Transplantation brings together the diverse members of the transplant community. The AST is recognized as an influential leader for the rights and needs of our patients. The Society is also recognized for its strong collaborative educational and informational resources. 

AST is instrumental in supporting the research community and fostering the translation of research into clinical practice. The Society advocates for research funding necessary for continued innovations in the science and practice of transplantation. Advancements in safer and more effective organ transplant therapies and novel, innovative strategies have resulted in significant improvements in immunosuppression for all transplant patients. Organ supply meets the demand as the result of successes in engineering of new organs, in addition to optimization of the donor management and allocation process; together these advances enhance donor organ integrity and function.

Goals and Objectives (3-5 years)

Goals represent outcome-oriented statements intended to guide and measure the organization’s future success. The achievement of each goal will move the organization towards the realization of its “Envisioned Future.” Supporting objectives further clarify direction and describe what the organization wants to have happen; a descriptive statement of what constitutes success in measurable terms.

Priority Key:
(I) = High importance for immediate investigation (first year)
(M) = If resources permit, begin objective within 2-3 years
(L) = If resources permit, begin objective within 3-5 years

Research
AST’s research program brings together clinicians and scientists to double long-term graft survival and optimize patient quality of life through transformative, multidisciplinary, basic, translational, and clinical research.

Objectives:
1. Increase interdisciplinary research efforts to integrate pre-clinical models with human clinical immunology. Priority: I
2. Promote opportunities to apply state-of-the-art technologies to transplant research. Priority: I
3. Define and communicate the value of transplant research. Priority: I
4. Stimulate research in organ injury and resuscitation. Priority: I
5. Link basic science with achieving clinical objectives to increase long-term graft survival. Priority: M
6. Discover the mechanism for chronic graft loss. Priority: L
7. Identify and eliminate barriers to clinical transplant tolerance induction. Priority: L

Development
AST has built a sustainable financial strategy enabling achievement of short and long-term goals.

Objectives:
1. Increase financial contributions from internal stakeholders.
Priority: I – annual member giving, board of directors and staff
Priority: M – other member strategies
2. Increase financial contributions from external groups.
Priority: I – transplant-related corporations and institutional supporters
Priority: M- non-transplant related corporations, Foundations, the general public, and individuals affected by transplantation

Education

Goal: AST has optimized the development and use of its educational content by AST members, as well as other audiences, including non-member transplant professionals, community-based healthcare professionals, and patients and their families.

Objectives:
1. Improve the process for approval and funding of educational activities within the AST structure. Priority: I
2. Assess program offerings in the context of the Envisioned Future. Priority: I
3. Enhance participation in available educational offerings. Priority: M
4. Increase availability of programs beyond AST. Priority: M/L

Advocacy
Goal: AST is recognized as the primary influencer and shaper of the legislative and regulatory landscapes within Congress, Federal Agencies, State Capitols, and the broader healthcare community.

Objectives:
1. Proactively advance and lead transplant public policy initiatives and prevent unintended consequences of congressional, regulatory, and state policy initiatives. Ongoing
2. Develop a private/public partnership with the FDA to advance transplant therapeutics. Priority: I
3. Become the clearinghouse for transplant information related to the Affordable Care Act. Priority: I/M
4. Develop quality metrics that define transplant value. Priority: I/M
5. Increase member involvement in advocacy. Priority: M